Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of "Hold" by Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) have been given a consensus rating of "Hold" by the twenty brokerages that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $125.17.

ZBH has been the subject of a number of research reports. Royal Bank of Canada cut their target price on shares of Zimmer Biomet from $140.00 to $130.00 and set an "outperform" rating for the company in a research report on Thursday, August 8th. JPMorgan Chase & Co. cut their target price on shares of Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating for the company in a research report on Monday, September 16th. Evercore ISI reissued an "in-line" rating and issued a $113.00 price objective on shares of Zimmer Biomet in a research report on Thursday, September 5th. Citigroup cut their price objective on shares of Zimmer Biomet from $134.00 to $120.00 and set a "neutral" rating for the company in a research report on Wednesday, July 10th. Finally, Morgan Stanley cut their price objective on shares of Zimmer Biomet from $130.00 to $120.00 and set an "equal weight" rating for the company in a research report on Monday, July 15th.

Zimmer Biomet Stock Up 1.2 %

Shares of NYSE ZBH opened at $107.74 on Friday. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. Zimmer Biomet has a 52 week low of $102.00 and a 52 week high of $133.90. The firm has a 50-day moving average price of $109.70 and a 200 day moving average price of $115.00. The stock has a market capitalization of $22.17 billion, a price-to-earnings ratio of 23.32, a price-to-earnings-growth ratio of 1.97 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.02. The company had revenue of $1.94 billion during the quarter, compared to analysts' expectations of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm's quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.82 earnings per share. Equities research analysts anticipate that Zimmer Biomet will post 8.01 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.89%. Zimmer Biomet's dividend payout ratio is currently 20.78%.

Institutional Investors Weigh In On Zimmer Biomet

Several institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its stake in shares of Zimmer Biomet by 12.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider's stock valued at $1,404,638,000 after purchasing an additional 1,215,935 shares during the period. American Century Companies Inc. grew its position in shares of Zimmer Biomet by 12.6% during the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock worth $701,521,000 after acquiring an additional 722,041 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of Zimmer Biomet by 6.7% during the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider's stock worth $365,163,000 after acquiring an additional 211,637 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Zimmer Biomet by 5.3% during the second quarter. Van ECK Associates Corp now owns 3,325,598 shares of the medical equipment provider's stock worth $360,927,000 after acquiring an additional 167,038 shares during the last quarter. Finally, Boston Partners grew its position in shares of Zimmer Biomet by 26.3% during the first quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider's stock worth $437,413,000 after acquiring an additional 691,191 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.